Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Poin...
June 29 2020 - 8:45AM
Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology
company focused on leveraging artificial intelligence (“A.I.”),
machine learning and genomic data to streamline the drug
development process and to identify the patients that will benefit
from its targeted oncology therapies, announced today that it
surpassed the milestone of 450 million curated data points being
utilized in its proprietary A.I. and machine learning-powered
platform, RADR® (Response Algorithm for Drug Positioning and
Rescue).
RADR® leverages genomic, transcriptomic, clinical and drug
sensitivity data points across more than 145 drug-tumor
interactions to predict the potential response cancer patients will
have to potential drugs, therefore enabling a more personalized
approach to therapy that is aimed at better outcomes. Lantern is
establishing collaborations and partnerships to expand the
functionality of RADR®, including algorithms that can operate
200 to 300 percent faster than its existing algorithms, enabling
the company to develop robust gene signatures that can be used to
guide patient enrollment in trials and as a companion diagnostic
(CDx). During the most recent data enrichment campaign, Lantern
focused on significantly increasing the depth and amount of data
for: non-small cell lung cancer, ovarian cancer, glioblastoma, and
gliomas. Reaching this milestone of over 450 million curated data
points for oncology drug development will bring greater precision
and speed in helping Lantern with its objective of personalizing
oncology therapy with reduced risk and cost.
“Our approach in leveraging machine learning to develop
biologically relevant, multi-gene signatures in days or weeks
allows our team to more efficiently review and test novel insights
about the complex mechanisms that can drive patient response to a
drug,” said Panna Sharma, CEO of Lantern Pharma.
As a pioneer in the application of machine learning to
oncology-focused drug development and clinical trial design,
Lantern has published gene signatures derived from RADR® as posters
and presentations at both ASCO and AACR. Lantern’s pipeline of
compounds includes one candidate in an active Phase 2 clinical
trial for metastatic, hormone-refractory prostate cancer using a
genomic signature for patient selection; another candidate in
preparation for a Phase 2 clinical trial in non-small cell lung
cancer in a targeted patient population; and a third candidate in
two preclinical programs for biomarker-defined solid tumors and
glioblastoma.
Mr. Sharma continued, “Because of the increasing availability of
large-scale biomarker, genomic and patient data, and rapidly
maturing technologies like artificial intelligence and machine
learning, oncology is undergoing a monumental shift in the way
cancer drugs are discovered, developed, studied, targeted, and
commercialized. Lantern is at the forefront of this transformation.
For Lantern, exceeding 450 million data points is a significant
milestone in our work, and demonstrates our commitment to
leveraging paradigm changing technologies that transform oncology
drug development with the ultimate objective of cost-effectively
personalizing treatment for patients.”
Lantern Pharma is ahead of the initial platform development
schedule, reaching 400 million data points by the end of 2020,
which puts Lantern on track to reach over 1 billion data points
earlier than expected. The developmental focus on increasing the
number of data points, and improving the performance of the
algorithms is expected to yield additional targeted indications for
Lantern’s current pipeline of drugs, and also help to uncover
additional compounds and therapies that can be in-licensed or
acquired and subsequently developed in a more efficient manner that
leverages the insights from Lantern’s data-driven, A.I.-enabled
approach.
The market opportunity for RADR® as a platform for the
development of targeted oncology therapies is significant. The
highly scalable RADR® platform can be leveraged in multiple
real-world applications, in addition to drug development,
including: identifying potential drug combinations, predicting
synergies with immune-oncology agents, developing companion
diagnostics (CDx) and evaluating compounds for therapeutic efficacy
and optimal positioning. Lantern is a pioneer in the adoption and
implementation of data-driven and machine-learning enabled
processes for drug development. The intersection of A.I., machine
learning and genomics is considered a rapidly growing trend as
researchers and investors turn to big data approaches to transform
the cost, risk and timeline of oncology drug development.
“Lantern Pharma is using genomics, machine-learning and big data
in an effort to develop potentially life-saving cancer drugs, and
our ability to fulfill this mission with greater efficiency and
speed will be enhanced by focusing on the overall strength and
scale of our platform,” concluded Mr. Sharma.
About Lantern PharmaLantern Pharma is a
clinical-stage biopharmaceutical company innovating the
repurposing, revitalization and development of precision
therapeutics in oncology. We leverage advances in machine learning,
genomics, and artificial intelligence by using a proprietary A.I.
platform to discover biomarker signatures that help identify
patients more likely to respond to our pipeline of cancer
therapeutics. Lantern’s focus is to improve the outcome for
patients by leveraging our technology to uncover, rescue and
develop abandoned or failed drugs. Our current pipeline of three
drugs, two in clinical stages and one in preclinical, focuses on
cancers that have unique and unmet clinical needs with a clearly
defined patient population. We believe that the use of machine
learning, genomics and computational methods can help accelerate
the revitalization, refocusing and development of small
molecule-based therapies. By targeting drugs to patients whose
genomic profile identifies them as having the highest probability
of benefiting from the drug, this approach represents the potential
to deliver best-in-class outcomes. Our team seeks out experienced
industry partners, world-class scientific advisors, and innovative
clinical-regulatory approaches to assist in delivering cancer
therapies to patients as quickly and efficiently as possible. For
more information, please visit the company's website at
www.lanternpharma.com or follow the company on Twitter
@lanternpharma
Contact: Kyle Evans, Public RelationsPhone: 646-699-1414Email:
lantern@fischtankpr.com
Forward-looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. The
forward-looking statements in this press release include, among
other things, statements relating to: the potential advantages of
our RADR® platform in identifying drug candidates and patient
populations that are likely to respond to a drug candidate; our
strategic plans to advance the development of any of our drug
candidates; our strategic plans to expand the number of data points
that our RADR® platform can access and analyze; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline the
drug development process and to identify patient populations that
would likely respond to a drug candidate; and our plans to discover
and develop drug candidates and to maximize their commercial
potential by advancing such drug candidates ourselves or in
collaboration with others. Additional information regarding the
risk factors to which we are subject is provided in greater detail
in our final prospectus for our initial public offering on June 10,
2020, on file with the Securities and Exchange Commission. You
may access our June 10, 2020 final prospectus under the investor
SEC filings tab of our website at www.lanternpharma.com or on the
SEC’s website at www.sec.gov. Given these risks and
uncertainties, we can give no assurances that our forward-looking
statements will prove to be accurate, or that any other results or
events projected or contemplated by our forward-looking statements
will in fact occur, and we caution investors not to place undue
reliance on these statements. All forward-looking statements in
this release represent our judgment as of the date hereof, and,
except as otherwise required by law, we disclaim any obligation to
update any forward-looking statements to conform the statement to
actual results or changes in our expectations.
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024